Sanofi symposium at NLC 2024

Biomarker-driven treatment of asthma – (when) is it worth it?

What is the value of biomarker-directed management of severe asthma in the current era of biologics? What is the recent evidence - is it really worth the trouble?

Welcome to this Sanofi symposium to hear the latest expert opinions on biomarker-directed treatment of asthma.

Program

Time: Friday 7.6.2024, 13:00-13:30
Place: Bysa 3, Clarion Hotel, Helsinki, Finland

Chair: Professor Lauri Lehtimäki, Tampere University & Tampere University Hospital

Biomarker-directed treatment as a way to improve asthma treatment
Professor Ian Pavord, Respiratory Medicine Unit & Oxford Respiratory NIHR BRC

Expert discussion: Biomarker-driven treatment of asthma – (when) is it worth it?

Professor Lauri Lehtimäki, Tampere University & Tampere University Hospital
Professor Ian Pavord, Respiratory Medicine Unit & Oxford Respiratory NIHR BRC